PARPi (PARP inhibitors) remarkably increases the level of PD-L1 by impairing hyperphosphorylation of glycogen synthase kinase 3β (GSK3β) (p-Ser9), which subsequently inhibits the antitumor immunity in both breast cancer cells and animal models. This evidence concerns the gene CD274 and breast carcinoma.